Navigation Links
Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
Date:2/3/2009

ing agreement on a registration plan with the Food and Drug Administration (FDA).

The Company is also currently conducting two additional randomized placebo-controlled Phase IIb clinical trials. The primary clinical endpoint for both of these trials is a reduction in pelvic pain associated with endometriosis, utilizing a Numeric Rating Scale. The first Phase IIb trial includes the Company's selected commercial formulation tablet in two once daily doses, (150 mg and 250 mg); this trial has completed the initial three-month placebo controlled dosing regimen and continues with an additional three-months of elagolix treatment. The Company will report top-line results from the first three months of treatment at the end of the first quarter of 2009. The second trial is a four arm comparator trial of two once daily doses of elagolix (150 mg and 250 mg), placebo or leuprolide depot. This trial is being conducted in Central Eastern Europe and is currently enrolling. Top-line data from this 3-month double-blind trial of approximately 180 patients is expected to be available in the third quarter of 2009.

The Company expects to hold an end of Phase II meeting with the FDA in late 2009.

Neurocrine is also investigating the potential of certain GnRH antagonists in treating other hormone-dependent diseases in men's and women's health.

Corticotropin Releasing Factor (CRF1) Receptor Antagonists for Anxiety/Depression and IBS

The CRF collaboration between Neurocrine and GSK has identified multiple unique high affinity and selective antagonists for the CRF1 receptor that are currently in clinical development for mood disorders and irritable bowel syndrome (IBS).

In a double-blind, randomized, placebo controlled, multiple dose study to evaluate the safety and efficacy of the CRF1 receptor antagonist, 876008, in approximately 130 patients with IBS, no statistically signif
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Webcast Alert: Neurocrine Announces 1Q08 Financial Results
2. Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets
3. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
4. Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies
5. New Jersey-Based Biotech Start-Up Nexomics Biosciences Gets Off the Ground
6. URMC, Lighthouse Biosciences Awarded U.S. Patent for Diagnostic Technology
7. URMC, Lighthouse Biosciences awarded US patent for diagnostic technology
8. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
9. CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform
10. Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus
11. Alexander R. Giaquinto, Ph.D., Joins Regado Biosciences as Senior Vice President of Regulatory Affairs and Quality Assurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Smart Flour Foods™ has been chosen as one ... trade magazine targeted toward food retailers. The delicious Uncured ... other attributes. Smart Flour Foods’ Uncured Pepperoni Pizza will ... print issue of Progressive Grocer as well as on ... on its superior performance in the following criteria: innovation ...
(Date:9/17/2014)... 2014 Cadiz Laser Spa offers ... procedures to clients throughout Central Texas. The newest ... Collagen Induction Therapy. Using the revolutionary Rejuvapen micro-needling ... help clients correct a wide variety of skin ... and Cadiz Laser Spa is currently offering a ...
(Date:9/17/2014)... News) -- Managing diabetes, quitting smoking, controlling high blood ... the risk for dementia -- even late in life, ... Report 2014, commissioned by Alzheimer,s Disease International, revealed that ... percent. The study noted that obesity and an inactive ... as high blood pressure. The researchers suggested ...
(Date:9/17/2014)... an analysis of genetic information among more than 87,000 ... found 23 new genetic variants common differences in ... for prostate cancer. The so-called "meta-analysis," believed to be ... mutations among men in a broad array of ethnic ... ancestry. , The meta-analysis combined information from smaller studies, ...
(Date:9/17/2014)... In a country where 77% of inhabitants ... basis, how can Americans find healthy and fulfilling ways ... Challenge , a 5-day interactive journey to putting stress ... From September 29th – October 3rd, the Hyland’s Stress ... specific topics that promote natural solutions for managing stress. ...
Breaking Medicine News(10 mins):Health News:Smart Flour Foods Wins 2014 Progressive Grocer Editor’s Pick Award 2Health News:Revolutionary Collagen Induction Therapy is Now Available at Cadiz Laser Spa 2Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 2Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 3Health News:Large study reveals new genetic variants that raise risk for prostate cancer 2Health News:Stress Less with the Hyland's 5-Day Stress Challenge 2
... it,s no better than standard treatment, one expert says, ... the indigestion and heartburn that bother many women as ... Indigestion is common during pregnancy, with up to 80 ... reflux, belching and bloating. Symptoms tend to worsen over ...
... - Europe Cosmetiques and Probiox announced today that both ... respect to oxidative stress profiling. Under this agreement, Europe ... and Mexico. , According to Manon Pilon, Founder President ... the leader in the Medical SPA industry, and is ...
... PEMBROKE, Bermuda, June 9 Allied World ... Assurance Company,Holdings, Ltd (NYSE: AWH ), today ... product offered in the United States. The,complimentary service, called ... crisis management resources in the,event of a catastrophe. , ...
... Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced today ... trial of sodium oxybate (JZP-6) for the treatment of ... Professional Sleep Societies (APSS) 2009 Annual Meeting in Seattle, ... (EULAR) Congress in Copenhagen, Denmark. , , Following ...
... Programs Designed to Address High Risks for New Dialysis Patients ... , DENVER, June 9 DaVita Inc. (NYSE: ... those diagnosed with chronic kidney disease (CKD), today commended Kidney ... Kidney Care (PEAK) campaign. Kidney Care Partners - a ...
... New techniques bring equivalent results without the potential dangers, ... Researchers say they,ve developed new techniques for reducing ... disease. , The use of these radiation-lowering strategies did ... computed tomography angiography (CCTA), an increasingly popular weapon in ...
Cached Medicine News:Health News: Acupuncture May Relieve Heartburn In Pregnancy 2Health News: Acupuncture May Relieve Heartburn In Pregnancy 3Health News:"Alliance between Europe Cosmetiques and Probiox brings new oxydative stress profiling technologies to North America" 2Health News:Allied World U.S. Announces Strategic Response(SM) - Complimentary Service Added to General Liability Lead Umbrella Product 2Health News:Allied World U.S. Announces Strategic Response(SM) - Complimentary Service Added to General Liability Lead Umbrella Product 3Health News:Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia 2Health News:Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia 3Health News:Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia 4Health News:DaVita Commends Kidney Care Partners for Launch of PEAK Campaign 2Health News:DaVita Commends Kidney Care Partners for Launch of PEAK Campaign 3Health News:Reduced-Radiation Heart Scans Don't Compromise on Quality 2
(Date:9/17/2014)... Calif. , Sept. 17, 2014 ... Prostate Vanguard, an awareness campaign to educate men about ... needle biopsies of the prostate. Annually, a million ... gland through the rectum. Multi-parametric MRI (MP-MRI) of the ... prostate cancer (CSPC). Men need to be fully ...
(Date:9/17/2014)... Sept. 17, 2014  Rebiotix Inc. announced this morning that ... product candidate, RBX2660 (microbiota suspension) will be presented in two ... in Philadelphia from October 8-12. ... the poster session on Thursday, October 9, 2014: ... Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety ...
(Date:9/17/2014)... SAN JOSE, Calif. , Sept. 17, 2014 /PRNewswire-iReach/ ... a laureate of The Tech Awards 2014, one of ... humanity and spark global change. The Tech Awards, a signature ... Applied Materials, Inc., selected Gradian as one of two laureates ... http://photos.prnewswire.com/prnh/20140917/146680 Gradian equips hospitals around ...
Breaking Medicine Technology:Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4Gradian Health Systems Named A 2014 Laureate of The Tech Awards 2Gradian Health Systems Named A 2014 Laureate of The Tech Awards 3
... New data presented at annual American Transplant Congress ... R. Carreno, MD, and colleagues in,the Departments of ... -,Lawrence Miller School of Medicine have corroborated the ... in recipients of,kidney transplants using a regular laboratory ...
... 2 Medarex, Inc.,(Nasdaq: MEDX ) ... Phase 1,study of MDX-1106 (ONO-4538: development code ... anti-PD-1 antibody. Data presented from patients with,recurrent ... the safety,tolerability and pharmacokinetic profile of single-dose ...
Cached Medicine Technology:University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 2University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 3University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 4Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 2Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 3Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 4
... This direct-acting inserter grasps the thinnest portion ... resulting in a minimum incision requirement. The ... the thicker center of the optic and ... resulting in delivery of an implant through ...
... inserter allows insertion of AMO SI-30 and SI-40 ... millimeters, and is perfect for clear corneal and ... has highly polished 6.5 millimeter rounded blades for ... tips of the blades have a .15 millimeter ...
... KR-8000PA Supra Auto-Kerato Refractometer combines an auto-refractor, ... mapping system all in a single, compact ... three times the diagnostic capabilities in one-third ... cost of the individual instruments. By implementing ...
Neomycin and Polymyxin B Sulfates and Hydrocortisone ophthalmic suspension is a sterile antimicrobial and anti-inflammatory suspension for ophthalmic use....
Medicine Products: